Ancient and advanced approaches for the treatment of an inflammatory autoimmune disease-psoriasis

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 31, Issue 4, 2014, Pages 331-364

  Garg, Tarun ^a   Rath, Goutam ^a   Goyal, Amit K ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Immunological approaches; Nanocarriers; Photodynamic therapy; Psoriasis; PUVA therapy

Indexed keywords

ALEFACEPT; AMINOLEVULINIC ACID; CALCIPOTRIOL; CLOBETASOL PROPIONATE; DENDRIMER; DRUG CARRIER; EFALIZUMAB; ETANERCEPT; ETHOSOME; INFLIXIMAB; INTERLEUKIN 4; LIPOSOME; METHOTREXATE; METHOXSALEN; MICROSPHERE; NANOCARRIER; NANOPARTICLE; NIOSOME; PHOTOFRIN; PIMECROLIMUS; PSORALEN; RAPAMYCIN; SIPLIZUMAB; SOLID LIPID NANOPARTICLE; TACALCITOL; TACROLIMUS; TEMOPORFIN; TRANSFEROSOME; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERTEPORFIN; ANTIINFLAMMATORY AGENT;

ACUPUNCTURE; ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BIOLOGICAL THERAPY; CELL MIGRATION; DIET THERAPY; ENVIRONMENT; ERYTHRODERMIC PSORIASIS; FLEXURAL PSORIASIS; GUTTATE PSORIASIS; HISTORY OF MEDICINE; HUMAN; HYDROGEL; IMMUNOTHERAPY; MICELLIZATION; MICROEMULSION; NAIL PSORIASIS; NANOTECHNOLOGY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; PUVA; QUALITY OF LIFE; REMISSION; SKIN DISEASE; SYSTEMIC THERAPY; T LYMPHOCYTE ACTIVATION; TOPICAL TREATMENT; TRADITIONAL MEDICINE; WATER TREATMENT; PROCEDURES;

ANTI-INFLAMMATORY AGENTS; DRUG CARRIERS; HUMANS; MEDICINE, TRADITIONAL; PSORIASIS;

EID: 84903380547     PISSN: 07434863     EISSN: 2162660X     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.2014010122     Document Type: Article

References (138)

1. Guttman-Yassky E, Dhingra N, Leung DY. New era of biologic therapeutics in atopic dermatitis. Expert Opin Biol Ther. 2013;13(4):549-61.
2. Ainali C, Valeyev N, Perera G, Williams A, Gudjonsson JE, Ouzounis CA. Transcriptome classification reveals molecular subtypes in psoriasis. BMC Genomics. 2012;13:472.
3. Garg T, Singh O, Arora S, Murthy R. Scaffold: a novel carrier for cell and drug delivery. Crit Rev Ther Drug Carrier Syst. 2012;29(1):1-63.
4. Dauden E, Castaneda S, Suarez C, Garcia-Campayo J, Blasco AJ, Aguilar MD. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol. 2013;27(11):1387-404.
5. Gagne L. [Psoriasis]. Perspect Infirm. 2013;10(5):14-5.
6. Rodriguez E, Weidinger S. [Genome-associated studies in chronic inflammatory dermatoses]. Internist (Berl). 2014;55(2):148-55.
7. Brunasso AM, Puntoni M, Aberer W, Delfino C, Fancelli L, Massone C. Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case-series study. Br J Dermatol. 2013;168(6):1243-51.
8. Refiker Ege M, Guray Y, Guray U, Demirkan B. Palmar psoriasis, a rare side effect of beta-blocker theraphy: a case report. Turk Kardiyol Dern Ars. 2012;40(5):451-3.
9. Bethea D, Fullmer B, Syed S, Seltzer G, Tiano J, Rischko C. Psoralen photobiology and photochemotherapy: 50 years of science and medicine. J Dermatol Sci. 1999;19(2):78-88.
10. Maradit-Kremers H, Dierkhising RA, Crowson CS, Icen M, Ernste FC, McEvoy MT. Risk and predictors of cardiovascular disease in psoriasis: a population-based study. Int J Dermatol. 2013;52(1):32-40.
11. Picardi A, Lega I, Tarolla E. Suicide risk in skin disorders. Clin Dermatol. 2013;31(1):47-56.
12. Garg T, Goyal AK. Iontophoresis: drug delivery system by applying an electrical potential across the skin. Drug delivery letters 2012;2(4):270-80.
13. Gordon-Elliott JS, Muskin PR. Managing the patient with psychiatric issues in dermatologic practice. Clin Dermatol. 2013;31(1):3-10.
14. Fraga NA, de Oliveira Mde F, Follador I, Rocha Bde O, Rego VR. Psoriasis and uveitis: a literature review. An Bras Dermatol. 2012;87(6):877-83.
15. Hawilo A, Zaraa I, Benmously R, Mebazaa A, El Euch D, Mokni M. [Erythrodermic psoriasis: epidemiological clinical and therapeutic features about 60 cases]. Tunis Med. 2011;89(11): 841-7.
16. Syed ZU, Khachemoune A. Inverse psoriasis: case presentation and review. Am J Clin Dermatol. 2011;12(2):143--6.
17. Henley ND. Rapid-onset skin rash. Guttate psoriasis. Am Fam Physician. 2012;86(4):361-2.
18. Aydin SZ, Castillo-Gallego C, Ash ZR, Marzo-Ortega H, Emery P, Wakefield RJ. Ultrasonographic assessment of nail in psoriatic disease shows a link between onychopathy and distal interphalangeal joint extensor tendon enthesopathy. Dermatology. 2012;225(3):231-5.
19. Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J. Biologic and nonbiologic systemic agents and phototherapy for treatment of chronic plaque psoriasis. 2012;12(13)-EHC144-EF.
20. Mease P. Update on treatment of psoriatic arthritis. Bull NYU Hosp Jt Dis. 2012;70(3):167-71.
21. Viguier M, Aubin F, Delaporte E, Pages C, Paul C, Beylot-Barry M. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis. Arch Dermatol. 2012;148(12): 1423-5.
22. Rai P, Kumar G, Chaudhary M. Psoriatic triad in a patient presenting with oligodontia. J Indian Soc Pedod Prev Dent. 2010;28(4):297-301.
23. Sultan SJ, Sameem F. Two contrasting post-zoster dermatomal phenomena. Skinmed. 2012;10(5):312-4.
24. Suarez-Farinas M, Li K, Fuentes-Duculan J, Hayden K, Brodmerkel C, Krueger JG. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol. 2012;132(11):2552-64.
25. Garg T, Murthy RSR, Goyal AK, Arora S, Malik B. Development, optimization and evaluation of porous chitosan scaffold formulation of gliclazide for the treatment of type-2 diabetes mellitus. Drug delivery letters. 2012;2(4):251-61.
26. Ingber A. [What's new in dermatology?]. Harefuah. 2012;151(10):553-4.
27. Mehta CS, Dave AR, Shukla VD. A clinical study of some Ayurvedic compound drugs in the assessment quality of life of patients with Eka Kushtha (psoriasis). Ayu. 2011;32(3):333-9.
28. Treloar V. Integrative dermatology for psoriasis: facts and controversies. Clin Dermatol. 2010;28(1):93-9.
29. Lesiak A, Narbutt J, Pawlaczyk M, Sysa-Jedrzejowska A, Krzyscin J. Vitamin D serum level changes in psoriatic patients treated with narrowband ultraviolet B phototherapy are related to the season of the irradiation. Photodermatol Photoimmunol Photomed. 2011;27(6):304-10.
30. Strohle A, Wolters M, Hahn A. Micronutrients at the interface between inflammation and infection-ascorbic acid and calciferol. Part 2: Calciferol and the significance of nutrient supplements. Inflamm Allergy Drug Targets. 2011;10(1):64-74.
31. Bartosinska JP, Pietrzak A, Szepietowski J, Dreiher J, Maciejewski R, Chodorowska G. Traditional Chinese medicine herbs-are they safe for psoriatic patients? Folia Histochem Cytobiol. 2011;49(2):201-5.
32. Gaston L, Crombez JC, Lassonde M, Bernier-Buzzanga J, Hodgins S. Psychological stress and psoriasis: experimental and prospective correlational studies. Acta Derm Venereol Suppl (Stockh). 1991;156:37-43.
33. Celia C, Cilurzo F, Trapasso E, Cosco D, Fresta M, Paolino D. Ethosomes(R) and transfersomes(R) containing linoleic acid: physicochemical and technological features of topical drug delivery carriers for the potential treatment of melasma disorders. Biomed Microdevices. 2012;14(1):119-30.
34. Draelos ZD. Moisturizing cream ameliorates dryness and desquamation in participants not receiving topical psoriasis treatment. Cutis. 2008;82(3):211-6.
35. Riyaz N, Arakkal FR. Spa therapy in dermatology. Ind J Dermatol Venereol Leprol. 2011;77(2): 128-34.
36. Kaur M, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis. Crit Rev Ther Drug Carrier Syst. 2014;31(1):49-88.
37. Goyal G, Garg T, Malik B, Chauhan G, Rath G, Goyal AK. Development and characterization of niosomal gel for topical delivery of benzoyl peroxide. Drug Deliv. 2013.
38. Garg T, Rath G, Goyal AK. Comprehensive review on additives of topical dosage forms for drug delivery. Drug Deliv. 2014.
39. Sarker DK. Engineering of nanoemulsions for drug delivery. Curr Drug Deliv. 2005;2(4): 297-310.
40. Hendriks AG, Keijsers RR, de Jong EM, Seyger MM, van de Kerkhof PC. Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(8):931-51.
41. Colombo GL, Di Matteo S, Bruno G, Girolomoni G, Vena GA. Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation. Clinicoecon Outcomes Res. 2012;4:261-8.
42. Castela E, Archier E, Devaux S, Gallini A, Aractingi S, Cribier B. Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy. J Eur Acad Dermatol Venereol. 2012;26 Suppl 3:47-51.
43. Sherlock ME, Walters T, Tabbers MM, Frost K, Zachos M, Muise A. Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn's disease and a potential association with IL-23 receptor polymorphisms. J Pediatr Gastroenterol Nutr. 2013;56(5):512-8.
44. Thapa RK, Yoo BK. Evaluation of the effect of tacrolimus-loaded liquid crystalline nanoparticles on psoriasis-like skin inflammation. J Dermatolog Treat. 2014;25(1):22-5.
45. Garg T, Singh O, Arora S, Murthy RSR. Dendrimer-a novel scaffold for drug delivery. Int J Pharm Sci Rev Res. 2011;7(2):211-20.
46. Jadhav KR, Shaikh IM, Ambade KW, Kadam VJ. Applications of microemulsion based drug delivery system. Curr Drug Deliv. 2006;3(3):267-73.
47. Garg T, Singh O, Arora S, Murthy RSR. Patented microencapsulation techniques and its applications. Journal of Pharmacy Research. 2011;4(7):2097-102.
48. Giovanna Brunasso AM, Michetti P, Fancelli L, Massone C. Cyclosporine as monotherapy for psoriasis in the setting of chronic HCV infection: a forgotten therapeutical option. Hepat Mon. 2012;12(5):349-52.
49. Pietrzak A, Chodorowska G, Jazienicka I, Osemlak P, Wawrzycki B, Terlecki P. Psoriatic erythroderma coexisting with erythema multiforme-like lesions induced by retinoids or retinoids combined with an antibiotic: case report. Dermatol Ther. 2011;24(6):587-90.
50. Janagond AB, Kanwar AJ, Handa S. Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study. J Eur Acad Dermatol Venereol. 2013;27(3):e384-9.
51. Malanin K. [A guest worker's multistage skin disease-a dermatologist's headache]. Duodecim. 2012;128(17):1803-7.
52. Baerveldt EM, Onderdijk AJ, Kurek D, Kant M, Florencia EF, Ijpma AS. Ustekinumab improves psoriasis-related gene expression in non-involved psoriatic skin without inhibition of the antimicrobial response. Br J Dermatol. 2013;168(5):990-8.
53. Bochot A, Fattal E. Liposomes for intravitreal drug delivery: a state of the art. J Control Release. 2012;161(2):628-34.
54. Saraswat A, Agarwal R, Katare OP, Kaur I, Kumar B. A randomized, double-blind, vehicle-controlled study of a novel liposomal dithranol formulation in psoriasis. J Dermatolog Treat. 2007;18(1):40-5.
55. Knudsen NO, Ronholt S, Salte RD, Jorgensen L, Thormann T, Basse LH. Calcipotriol delivery into the skin with PEGylated liposomes. Eur J Pharm Biopharm. 2012;81(3):532-9.
56. Srisuk P, Thongnopnua P, Raktanonchai U, Kanokpanont S. Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment. Int J Pharm. 2012;427(2):426-34.
57. El-Ridy MS, Abdelbary A, Essam T, El-Salam RM, Kassem AA. Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin. Drug Dev Ind Pharm. 2011;37(12):1491-508.
58. Rajera R, Nagpal K, Singh SK, Mishra DN. Niosomes: a controlled and novel drug delivery system. Biol Pharm Bull. 2011;34(7):945-53.
59. Agarwal R, Katare OP, Vyas SP. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm. 2001;228(1-2):43-52.
60. Lakshmi PK, Devi GS, Bhaskaran S, Sacchidanand S. Niosomal methotrexate gel in the treatment of localized psoriasis: phase I and phase II studies. Ind J Dermatol Venereol Leprol. 2007;73(3):157-61.
61. Marianecci C, Rinaldi F, Mastriota M, Pieretti S, Trapasso E, Paolino D. Anti-inflammatory activity of novel ammonium glycyrrhizinate/niosomes delivery system: human and murine models. J Control Release. 2012;164(1):17-25.
62. Parnami N, Garg T, Rath G, Goyal AK. Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy. Artif Cells Nanomed Biotechnol. 2013.
63. Rajan R, Jose S, Mukund VP, Vasudevan DT. Transferosomes-a vesicular transdermal delivery system for enhanced drug permeation. J Adv Pharm Technol Res. 2011;2(3):138-43.
64. Patel RB, Parikh RH. Preparation and formulation of transferosomes containing an antifungal agent for transdermal delivery: application of Plackett-Burman design to identify significant factors influencing vesicle size. J Pharm Bioallied Sci. 2012;4(Suppl 1):S60-1.
65. Rother M, Lavins BJ, Kneer W, Lehnhardt K, Seidel EJ, Mazgareanu S. Efficacy and safety of epicutaneous ketoprofen in transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial. Ann Rheum Dis. 2007;66(9):1178-83.
66. Ainbinder D, Paolino D, Fresta M, Touitou E. Drug delivery applications with ethosomes. J Biomed Nanotechnol. 2010;6(5):558-68.
67. Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release. 2007;123(2):148-54.
68. Fang YP, Huang YB, Wu PC, Tsai YH. Topical delivery of 5-aminolevulinic acid-encapsulated ethosomes in a hyperproliferative skin animal model using the CLSM technique to evaluate the penetration behavior. Eur J Pharm Biopharm. 2009;73(3):391-8.
69. Raza K, Singh B, Lohan S, Sharma G, Negi P, Yachha Y. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. Int J Pharm. 2013;456(1):65-72.
70. Kojarunchitt T, Hook S, Rizwan S, Rades T, Baldursdottir S. Development and characterisation of modified poloxamer 407 thermoresponsive depot systems containing cubosomes. Int J Pharm. 2011;408(1-2):20-6.
71. Entezari MH, Ghows N. Micro-emulsion under ultrasound facilitates the fast synthesis of quantum dots of CdS at low temperature. Ultrason Sonochem. 2011;18(1):127-34.
72. Arleth L, Svensson B, Mortensen K, Pedersen JS, Olsson U. Block-copolymer micro-emulsion with solvent-induced segregation. Langmuir. 2007;23(4):2117-25.
73. Pereira TM, Vieira AP, Fernandes JC, Sousa-Basto A. Cyclosporin A treatment in severe childhood psoriasis. J Eur Acad Dermatol Venereol. 2006;20(6):651-6.
74. Baboota S, Alam MS, Sharma S, Sahni JK, Kumar A, Ali J. Nanocarrier-based hydrogel of betamethasone dipropionate and salicylic acid for treatment of psoriasis. Int J Pharm Investig. 2011;1(3):139-47.
75. Shintani Y, Kaneko N, Furuhashi T, Saito C, Morita A. Safety and efficacy of a fixed-dose cyclosporin microemulsion (100 mg) for the treatment of psoriasis. J Dermatol. 2011;38(10):966-72.
76. Castonguay A, Wilson E, Al-Hajaj N, Petitjean L, Paoletti J, Maysinger D. Thermosensitive dendrimer formulation for drug delivery at physiologically relevant temperatures. Chem Commun (Camb). 2011;47(44):12146-8.
77. Wang Z, Itoh Y, Hosaka Y, Kobayashi I, Nakano Y, Maeda I. Novel transdermal drug delivery system with polyhydroxyalkanoate and starburst polyamidoamine dendrimer. J Biosci Bioeng. 2003;95(5):541-3.
78. Fuchs S, Kapp T, Otto H, Schoneberg T, Franke P, Gust R. A surface-modified dendrimer set for potential application as drug delivery vehicles: synthesis, in vitro toxicity, and intracellular localization. Chemistry. 2004;10(5):1167-92.
79. Gardikis K, Fessas D, Signorelli M, Dimas K, Tsimplouli C, Ionov M. A new chimeric drug delivery nano system (chi-aDDnS) composed of PAMAM G 3.5 dendrimer and liposomes as doxorubicin's carrier. In vitro pharmacological studies. J Nanosci Nanotechnol. 2011;11(5):3764-72.
80. Agrawal U, Mehra NK, Gupta U, Jain NK. Hyperbranched dendritic nanocarriers for topical delivery of dithranol. J Drug Target. 2013;21(5):497-506.
81. Valerii MC, Benaglia M, Caggiano C, Papi A, Strillacci A, Lazzarini G. Drug delivery by polymeric micelles: an in vitro and in vivo study to deliver lipophilic substances to colonocytes and selectively target inflamed colon. Nanomedicine. 2013;9(5):675-85.
82. Xu W, Ling P, Zhang T. Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J Drug Deliv. 2013;2013:340315.
83. Ehrlich A, Booher S, Becerra Y, Borris DL, Figg WD, Turner ML. Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study. J Am Acad Dermatol. 2004;50(4):533-40.
84. Gao SQ, Maeda T, Okano K, Palczewski K. A microparticle/hydrogel combination drug-delivery system for sustained release of retinoids. Invest Ophthalmol Vis Sci. 2012;53(10):6314-23.
85. Cetin EO, Gundogdu E, Kirilmaz L. Novel microparticle drug delivery systems based on chitosan and Eudragit(R) RSPM to enhance diltiazem hydrochloride release property. Pharm Dev Technol. 2012;17(6):741-6.
86. Badilli U, Sen T, Tarimci N. Microparticulate based topical delivery system of clobetasol propionate. AAPS PharmSciTech. 2011;12(3):949-57.
87. Couvreur P. Nanoparticles in drug delivery: past, present and future. Adv Drug Deliv Rev. 2013;65(1):21-3.
88. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine. 2012;8(2):147-66.
89. Ridolfi DM, Marcato PD, Justo GZ, Cordi L, Machado D, Duran N. Chitosan-solid lipid nanoparticles as carriers for topical delivery of tretinoin. Colloids Surf B Biointerfaces. 2012;93:36-40.
90. Agrawal U, Gupta M, Vyas SP. Capsaicin delivery into the skin with lipidic nanoparticles for the treatment of psoriasis. Artif Cells Nanomed Biotechnol. 2013.
91. Thapa RK, Yoo BK. Design and in vitro evaluation of finasteride-loaded liquid crystalline nanoparticles for topical delivery. J Dermatolog Treat. AAPS PharmSciTech. 2013;14(1):45-52.
92. Garg T, Singh S, Goyal AK. Stimuli-sensitive hydrogels: an excellent carrier for drug and cell delivery. Crit Rev Ther Drug Carrier Syst. 2013;30(5):369-409.
93. Ali MF, Salah M, Rafea M, Saleh N. Liposomal methotrexate hydrogel for treatment of localized psoriasis: preparation, characterization and laser targeting. Med Sci Monit. 2008;14(12):PI66-74.
94. Patel T, Bhutani T, Busse KL, Koo J. Evaluating the efficacy and safety of calcipotriene/betamethasone ointment occluded with a hydrogel patch: a 6-week bilaterally controlled, investigator-blinded trial. Cutis. 2011;88(3):149-54.
95. Park KK, Kamangar F, Heller M, Lee E, Bhutani T, Busse K. Instant barrier repair: A pilot study investigating occlusion with a new hydrogel patch for the treatment of atopic dermatitis. J Dermatolog Treat. 2013;24(2):119-21.
96. Gomes AJ, Lunardi CN, Lunardi LO, Pitol DL, Machado AE. Identification of psoralen loaded PLGA microspheres in rat skin by light microscopy. Micron. 2008;39(1):40-4.
97. Bikkad ML, Nathani AH, Mandlik SK, Shrotriya SN, Ranpise NS. Halobetasol propionate-loaded solid lipid nanoparticles (SLN) for skin targeting by topical delivery. J Liposome Res. 2013.
98. Ward NL, Loyd CM, Wolfram JA, Diaconu D, Michaels CM, McCormick TS. Depletion of antigenpresenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice. Br J Dermatol. 2011;164(4):750-8.
99. Kilfoyle BE, Sheihet L, Zhang Z, Laohoo M, Kohn J, Michniak-Kohn BB. Development of paclitaxel-TyroSpheres for topical skin treatment. J Control Release. 2012;163(1):18-24.
100. Shah PP, Desai PR, Patel AR, Singh MS. Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugs. Biomaterials. 2012;33(5):1607-17.
101. Owczarek A, Pluta J, Kogut J. [Evaluation properties of hydrogels with simvastatin prepared on Carbopol 2020]. Polim Med. 2010;40(1):57-64.
102. Thapa RK, Yoo BK. Evaluation of the effect of tacrolimus-loaded liquid crystalline nanoparticles on psoriasis-like skin inflammation. J Dermatolog Treat. 2014;25(1):22-5.
103. Trapasso E, Cosco D, Celia C, Fresta M, Paolino D. Retinoids: new use by innovative drug-delivery systems. Expert Opin Drug Deliv. 2009;6(5):465-83.
104. Zhang J, Smith E. Percutaneous permeation of betamethasone 17-valerate incorporated in lipid nanoparticles. J Pharm Sci. 2011;100(3):896-903.
105. Hazarika D. Generalized pustular psoriasis of pregnancy successfully treated with cyclosporine. Indian J Dermatol Venereol Leprol. 2009;75(6):638.
106. Khandavilli S, Panchagnula R. Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats. J Invest Dermatol. 2007;127(1):154-62.
107. Benson HA. Elastic liposomes for topical and transdermal drug delivery. Curr Drug Deliv. 2009;6(3):217-26.
108. Tung D, Cheung PH, Kaur P, Foreman O, Kavirayani A, Hain HS. Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models. Pharmacology. 2011;88(1-2):100-13.
109. Nagle A, Goyal AK, Kesarla R, Murthy RSR. Efficacy study of vesicular gel containing methotrexate and menthol combination on parakeratotic rat skin model. J Liposome Res. 2011;21(2):134-40.
110. Strohal R, Chimenti S, Vena GA, Girolomoni G. Etanercept provides an effective, safe and flexible short-and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence. J Dermatolog Treat. 2013;24(3):199-208.
111. Paul C, van de Kerkhof P, Puig L, Unnebrink K, Goldblum O, Thaci D. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study. Eur J Dermatol. 2012;22(6):762-9.
112. Wee JS, Petrof G, Jackson K, Barker JN, Smith CH. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre. Br J Dermatol. 2012;167(2):411-6.
113. Sivamani RK, Goodarzi H, Garcia MS, Raychaudhuri SP, Wehrli LN, Ono Y. Biologic Therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clin Rev Allergy Immunol. 2013;44(2):121-40.
114. Montesu MA, Addis GM, Satta R, Cottoni F. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature. G Ital Dermatol Venereol. 2011;146(4): 273-81.
115. Scheinfeld N. Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists. J Dermatolog Treat. 2006;17(4):229-34.
116. Baumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007;6(1):17-26.
117. Laws PM, Young HS. Topical treatment of psoriasis. Expert Opin Pharmacother. 2010;11(12):1999-2009.
118. Zhu K, Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol. 2001;116(2):203-8.
119. Diamantino F, Ferreira A. [Future perspectives in the treatment of psoriasis: news in biological therapies]. Acta Med Port. 2011;24(6):997-1004.
120. Wilsmann-Theis D, Martin S, Reber M, Kwiek B, Bieber T, Novak N. Biologicals dramatic advances in the treatment of psoriasis. Curr Pharm Des. 2006;12(8):989-99.
121. Calzavara-Pinton PG, Rossi MT, Aronson E, Sala R. A retrospective analysis of real-life practice of off-label photodynamic therapy using methyl aminolevulinate (MAL-PDT) in 20 Italian dermatology departments. Part 1: Inflammatory and aesthetic indications. Photochem Photobiol Sci. 2012;12(1):148-57.
122. Wang CY, Wang X, Wang Y, Zhou T, Bai Y, Li YC. Photosensitization of phycocyanin extracted from Microcystis in human hepatocellular carcinoma cells: Implication of mitochondria-dependent apoptosis. J Photochem Photobiol B. 2012;117:70-9.
123. Zhou QX, Lei WH, Hou YJ, Chen YJ, Li C, Zhang BW. BODIPY-modified Ru(ii) arene complex-a new ligand dissociation mechanism and a novel strategy to red shift the photoactivation wavelength of anticancer metallodrugs. Dalton Trans. 2013;42(8):2786-91.
124. Ratkay LG, Waterfield JD, Hunt DW. Photodynamic therapy in immune (non-oncological) disorders: focus on benzoporphyrin derivatives. BioDrugs. 2000;14(2):127-35.
125. Dragicevic-Curic N, Winter S, Krajisnik D, Stupar M, Milic J, Graefe S. Stability evaluation of temoporfin-loaded liposomal gels for topical application. J Liposome Res. 2010;20(1):38-48.
126. El-Domyati M, Moftah NH, Nasif GA, Abdel-Wahab HM, Barakat MT, Abdel-Aziz RT. Evaluation of apoptosis regulatory proteins in response to PUVA therapy for psoriasis. Photodermatol Photoimmunol Photomed. 2013;29(1):18-26.
127. Tilkorn DJ, Schaffran A, Al Benna S, Hauser J, Steinau HU, Ring A. severe burn injuries induced by PUVA chemotherapy. J Burn Care Res. 2013;34(3):e195-200.
128. Khandpur S, Sharma VK. Comparison of clobetasol propionate cream plus coal tar vs. topical psoralen and solar ultraviolet A therapy in palmoplantar psoriasis. Clin Exp Dermatol. 2011;36(6):613-6.
129. Ravic-Nikolic A, Radosavljevic G, Jovanovic I, Zdravkovic N, Mitrovic S, Pavlovic S. Systemic photochemotherapy decreases the expression of IFN-gamma, IL-12p40 and IL-23p19 in psoriatic plaques. Eur J Dermatol. 2011;21(1):53-7.
130. Brazzelli V, Barbagallo T, Prestinari F, Rona C, De Silvestri A, Trevisan V. Non-invasive evaluation of tacalcitol plus puva versus tacalcitol plus UVB-NB in the treatment of psoriasis: "right-left intraindividual pre/post comparison design. " Int J Immunopathol Pharmacol. 2005;18(4):755-60.
131. Salem SA, Barakat MA, Morcos CM. Bath psoralen+ultraviolet A photochemotherapy vs. narrow band-ultraviolet B in psoriasis: a comparison of clinical outcome and effect on circulating T-helper and T-suppressor/cytotoxic cells. Photodermatol Photoimmunol Photomed. 2010;26(5):235-42.
132. Mascaro JM. Vitamin D and psoralen plus UVA radiation. Cutis. 2002;70(5 Suppl):13-5.
133. Klosner G, Trautinger F, Knobler R, Neuner P. Treatment of peripheral blood mononuclear cells with 8-methoxypsoralen plus ultraviolet A radiation induces a shift in cytokine expression from a Th1 to a Th2 response. J Invest Dermatol. 2001;116(3):459-62.
134. Kist JM, Van Voorhees AS. Narrowband ultraviolet B therapy for psoriasis and other skin disorders. Adv Dermatol. 2005;21:235-50.
135. Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol. 2002;82(2):131-5.
136. Bowman PH, Maloney JE, Koo JY. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. J Am Acad Dermatol. 2002;46(6):907-13.
137. Fogh K, Kragballe K. New vitamin D analogs in psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3(2):199-204.
138. Weinstein GD, Goldfaden G, Frost P. Methotrexate. Mechanism of action on DNA synthesis in psoriasis. Arch Dermatol. 1971;104(3):236-43.